IGM Biosciences Q2 2024 GAAP EPS $(0.79) May Not Be Comparable To $0.04 Estimate, Sales $1.254 May Not Be Comparable To $54.313M Estimate
Portfolio Pulse from Benzinga Newsdesk
IGM Biosciences reported a Q2 2024 GAAP EPS of $(0.79), which is not comparable to the $0.04 estimate. The company also reported sales of $1.254 million, which is not comparable to the $54.313 million estimate.
August 14, 2024 | 11:19 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
IGM Biosciences reported a Q2 2024 GAAP EPS of $(0.79) and sales of $1.254 million, both of which are not comparable to the estimates of $0.04 and $54.313 million, respectively.
The significant discrepancy between the reported EPS and sales figures compared to the estimates is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100